Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for EBM Technologies's Debt-to-EBITDA or its related term are showing as below:
ROCO:8409'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -26.57 Med: -0.58 Max: 33.24
Current: 1.53
During the past 13 years, the highest Debt-to-EBITDA Ratio of EBM Technologies was 33.24. The lowest was -26.57. And the median was -0.58.
ROCO:8409's Debt-to-EBITDA is ranked better than 60.46% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs ROCO:8409: 1.53
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
EBM Technologies Debt-to-EBITDA Related Terms
EBM Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for EBM Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8409 vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, EBM Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EBM Technologies Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, EBM Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EBM Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
EBM Technologies (ROCO:8409) has a Debt-to-EBITDA of -1.13 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EBM Technologies. According to the industry distribution chart, EBM Technologies ranks #189 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 39.5%.
Is EBM Technologies' Debt-to-EBITDA too high?
EBM Technologies' current Debt-to-EBITDA is -1.13. Based on the distribution chart, EBM Technologies ranks #189 out of 478 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, EBM Technologies has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EBM Technologies' Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, EBM Technologies ranks #189 out of 478 companies for Debt-to-EBITDA. This puts EBM Technologies in the upper half of its industry. The industry median Debt-to-EBITDA is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EBM Technologies. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EBM Technologies's current Debt-to-EBITDA is -1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EBM Technologies stock overvalued right now?
Based on GuruFocus' analysis, EBM Technologies (ROCO:8409) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$25.25, compared to a current price of NT$18.30 — trading 27.5% below its estimated fair value. The current Debt-to-EBITDA is -1.13. EBM Technologies' overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For EBM Technologies (ROCO:8409), the current Debt-to-EBITDA is -1.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EBM Technologies (ROCO:8409) Overvalued in 2026?
Based on GuruFocus' analysis, EBM Technologies stock appears to be undervalued.
The current stock price of NT$18.30 is trading 27.5% below its estimated GF Value™ of NT$25.25.
GuruFocus considers EBM Technologies to be Modestly Undervalued.
Key valuation signals for ROCO:8409:
Debt-to-EBITDA: -1.13
GF Value™: NT$25.25 vs. price of NT$18.30 (27.5% below fair value)
No single metric tells the full story. See the ROCO:8409 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EBM Technologies Inc is engaged in picture archiving and communication systems. Its products include EBM diagnostic and reviewing station, EBM storage and utility server, and EBM breast imaging for PACS. The company develops and markets medical information technology solutions; and provides to the health sector.
64GF Score
Get the complete analysis for ROCO:8409
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8409 has been successfully added to your 
